expenses was primarily attributable to the CETHRIN license fee of $10
million in 2006.
-- General and administrative (G&A) expenses were $8.4 million in 2007 as
compared to $7.9 million in 2006. The increase in G&A expenses was
primarily related to higher commercialization and communication costs
and higher headcount offset by lower costs related to our collaboration
and fundraising efforts.
Conference Call Access Information
The Company will host a conference call to discuss results on, April 1,
2008, at 10:00 a.m. Eastern Daylight Time. The call can be accessed by
dialing dial 877-718-5104 (or 719-325-4843 for international
participants). The participant pass code for this conference call is
7767549. Please dial in 5 to 10 minutes prior to the scheduled start
time. A replay of the call will be posted on the Investor Relations
section of the website, http://www.alseres.com, within 48 hours following
the conference call and will be available through Tuesday, April 15, 2008.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company's
energy and focus is reflected in several important initiatives. CETHRIN, a
recombinant-protein-based drug designed to promote nerve repair after acute
spinal cord injury, demonstrated positive interim results in a Phase I/IIa
clinical trial. The Company's research and pre-clinical programs include,
Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for
the treatment of ocular injury and disease and research programs directed
at a number of regenerative ther
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved